Komipharm International Co., Ltd. (KOSDAQ:041960)
9,450.00
-400.00 (-4.06%)
Sep 17, 2026, 3:30 PM KST
Komipharm International Revenue
Komipharm International had revenue of 16.70B KRW in the quarter ending June 30, 2026, with 22.11% growth. This brings the company's revenue in the last twelve months to 53.02B, down -3.27% year-over-year. In the year 2025, Komipharm International had annual revenue of 52.47B, down -10.74%.
Revenue (ttm)
53.02B
Revenue Growth
-3.27%
P/S Ratio
12.89
Revenue / Employee
329.30M
Employees
161
Market Cap
683.63B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 52.47B | -6.31B | -10.74% |
| Dec 31, 2024 | 58.78B | 16.13B | 37.83% |
| Dec 31, 2023 | 42.65B | 2.85B | 7.15% |
| Dec 31, 2022 | 39.80B | 3.95B | 11.03% |
| Dec 31, 2021 | 35.85B | -1.31B | -3.53% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| GC Corp. | 2.49T |
| Chabiotech | 1.31T |
| Medy-Tox | 251.08B |
| Onconic Therapeutics | 82.17B |
| Pharmicell | 23.94B |
| GI Innovation | 5.50B |
| AbClon | 5.31B |
| Kolon TissueGene | 4.80B |